The first once-weekly basal insulin approved in the United States is now stocked at 70,000 retail pharmacies nationwide, following the manufacturer's nationwide launch announcement. The product, insulin icodec-abae, sold by Novo Nordisk as Awiqli, was cleared in March for adults with type 2 diabetes and replaces seven basal injections a week with one.
For patients, the change is easiest to understand as an annual figure. A daily basal regimen means roughly 365 injections a year. A weekly regimen means 52. Tom Scales, a senior vice president at the company, said the product "reduces the frequency of daily basal insulin injections from 7 to 1 per week."
The population involved is large. More than 36 million people in the United States have type 2 diabetes, and roughly 22 percent of them, about 8 million people, require daily insulin injections to control blood glucose, according to figures reported by the Washington Post.
The Trade-Off Behind a Longer Acting Drug
The convenience comes from the same property that requires caution. A once-weekly insulin stays in the body much longer than a daily one, so a dosing mistake takes longer to correct.
That is why European regulators required the company to issue educational materials explaining how patients can avoid errors and mix-ups when switching from a daily long-acting insulin, and why the product is dosed on the same day each week. Switching from a daily basal insulin involves converting the total weekly requirement rather than making a simple substitution, and the first dose may be handled differently from later ones. None of that is something a patient should work out alone.
Approval rested on the ONWARDS phase 3a program, four randomized trials enrolling roughly 2,680 adults with type 2 diabetes who were not well controlled on other treatments. The weekly product met its primary endpoint of noninferiority for HbA1c reduction against daily basal insulin comparators, meaning blood sugar control was shown to be not meaningfully worse, rather than better, as summarized in clinical coverage of the launch. Reported safety findings included hypoglycemia, injection site reactions, rash, swelling in the extremities, and weight gain.
Charles Alexander, an independent industry consultant not involved in the trials, told Medscape Medical News that the product "definitely adds a convenient regimen for those with T2D who need insulin," particularly for people already taking a weekly injectable.
Pricing, Copays, and the Patients Who Still Pay Full Price
The list price is $99 per package, according to reporting on the launch terms. Through the manufacturer's savings programs, eligible patients with commercial insurance or Medicare may pay as little as $35 a month, and uninsured patients may pay $55 a month through a self-pay route.
Those figures come with conditions worth reading before assuming them. Savings card terms exclude patients whose plans use copay accumulator or maximizer arrangements, which do not credit manufacturer assistance toward a deductible. Coverage also varies by plan. The company says it expects the product to be covered for most eligible adults with type 2 diabetes, but formulary placement is decided plan by plan, and a drug that is stocked is not automatically covered at a preferred tier.
Federal and state cost caps sit alongside these programs. Medicare Part D limits insulin cost-sharing, and many states cap insulin copays for state-regulated commercial plans. Patients paying cash should compare the manufacturer route against pharmacy cash prices rather than assuming one is lower. MedicalDaily has previously reported on the gap between list prices and what patients pay, a distinction that matters more in diabetes than in almost any other category.
Adults with Type 1 Diabetes Are Not Covered by This Approval
The indication is narrow and deliberately so. The product is approved as an adjunct to diet and exercise for adults with type 2 diabetes, and it is not approved for type 1 diabetes in the United States.
That limit reflects the regulatory history. The Food and Drug Administration issued a complete response letter in 2024 to an earlier application covering both major types of diabetes, citing manufacturing questions and concerns about hypoglycemia risk in type 1 diabetes. An advisory panel voted against use in type 1 while raising no comparable safety concern for type 2, and the company subsequently focused on the population where its data were strongest, as described in Medscape's account of the approval decision.
Published reviews of weekly insulins reinforce that split. In type 2 diabetes, rates of clinically significant and severe hypoglycemia have looked broadly similar to those of daily regimens. In type 1 diabetes, pooled trial data have reported more injection site reactions, more serious adverse events, and slightly weaker HbA1c reduction with weekly products than with daily ones. European regulators reached a similar conclusion, advising that people with type 1 diabetes start a weekly insulin only when there is a clear benefit. Children and adolescents were not part of the U.S. approval either.
Questions Worth Raising at the Next Diabetes Appointment
Nobody currently using a daily basal insulin should change or stop it without speaking to the clinician who prescribed it. Insulin adjustment is individualized, and an unsupervised switch carries real risk of both high and low blood sugar.
For patients who want to explore the option, a short list of questions covers most of the ground. Whether the prescriber considers a weekly basal insulin appropriate given current control, kidney function, and other medications. Whether the plan covers it and at what tier. How the weekly dose would be calculated from the current daily dose, and how titration would be monitored in the first weeks. What is the plan if a dose is taken late, and what glucose monitoring is expected during the transition? Patients with a history of severe hypoglycemia or unstable glucose should ask specifically how that changes the calculation.
What is not yet known is how the product performs outside trial conditions, where dosing errors, missed appointments, and inconsistent monitoring are more common than in a controlled study. Real-world safety data will accumulate over the coming year. Eli Lilly has sought U.S. approval for a competing once-weekly insulin, efsitora alfa, which could eventually expand options and affect pricing.
Key Questions Answered
Who can use this insulin? It is approved as an adjunct to diet and exercise for adults with type 2 diabetes. It is not approved in the United States for type 1 diabetes or for children.
How much does it cost? The list price is $99 per package. Eligible patients with commercial insurance or Medicare may pay as little as $35 a month through the manufacturer's program, and uninsured patients may pay $55 a month.
Is it as effective as daily insulin? In the trials supporting approval, it met a noninferiority standard for blood sugar reduction against commonly used daily basal insulins in adults with type 2 diabetes. That means comparable control, not better control.
What are the main side effects? Reported findings include hypoglycemia, injection site reactions, rash, swelling in the extremities, and weight gain. Serious allergic reactions have also been described with insulin products.
Can I switch to my current insulin on my own? No. The weekly dose is converted from a patient's total weekly basal requirement, and the transition needs to be planned and monitored by a prescribing clinician.
What happens if a dose is taken late or twice? Because the drug stays in the body far longer than a daily insulin, dosing errors take longer to resolve. Patients should ask their clinician for written instructions before starting.
Will insurance cover it? Coverage is decided plan by plan. Patients should confirm formulary tier and prior authorization requirements with their own plan rather than assuming coverage.
